EN DE
Watch Jw Cayman Therapeutics Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Jw Cayman Therapeutics Co Ltd (2126) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Jw Cayman Therapeutics Co Ltd stock HK$0.39, price HK$2.50, that is 84.4% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG5210T1040

JC Jw Cayman Therapeutics Co Ltd logo Thin data Nov 8, 2026

Jw Cayman Therapeutics Co Ltd

2126 · HK
Very expensive, weak quality

Our calculation puts a fair price 84% below what the stock costs today.

Low debt
Quality 45/100
Mixed Growth (revenue 3y +23.8 %/yr in CNY)
Mixed vs. peers (5/10)
Fair value HK$0.3900 · Strongly overvalued (−84.4%)
Loss-making · -117.3% net margin (TTM)
Negative free cash flow
Narrow moat 5/100
Thin data
Watch Jw Cayman Therapeutics Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$31.00 HK$1.19 Fair Value HK$0.3900 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range HK$1.19 – HK$31.00 · fair‑value band HK$0.2600 – HK$0.4900 · the HK$2.50 price screens above the HK$0.3900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Jw Cayman Therapeutics Co in your weekly email

Every Wednesday you see whether Jw Cayman Therapeutics Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China.

Show moreShow less

The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer.

It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection ("relma-cel") as a potential treatment for systemic lupus erythematosus ("SLE"), and progressed development of products for the treatment of solid tumors, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease.

The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases.

It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer.

In addition, the company engages in drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities.

JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.

Stock analysis

Jw Cayman Therapeutics Co Ltd (2126) currently trades at HK$2.50, while our model-based Fair Value estimate is HK$0.3900, 84% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: HK$0.2600 (bear) to HK$0.4900 (bull), the price of HK$2.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Jw Cayman Therapeutics Co Ltd reported revenue of 276M CNY in FY2025 versus 30.8M CNY in FY2021, a compound +73.1%/yr. Reported net income was −541M CNY in FY2025.

Key figures

Market cap HK$1.0B (≈ $133M) Micro · P/S ratio 3.18 · Return on equity −49.7% · Return on assets (EBIT) −28.7% (5-year average) · Operating margin −83.5% · Revenue (TTM) 289M CNY · Revenue growth (YoY) +4.7% · Free cash flow −78.5M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 32% below its 52-week high and 67% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −84%, 2126 screens richer than that median.

Fair Value models

Bear HK$0.2600 Fair Value HK$0.3900 Bull HK$0.4900
Price HK$2.50 · Downside -84.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) HK$0.2600 HK$0.3900 HK$0.4900 54
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.2600 HK$0.3900 HK$0.4900 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 66
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 48
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 20
Distance to the 52-week high, does not count
New shares 79
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+74.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.8%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+178.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,711.8% (2019) → −87.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2126 screens overvalued: fair value 84% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Jw Cayman Therapeutics Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −84.4% · Bottom 25%
Profitability
Return on assets −54.8% · Bottom 25%
Net margin (12 months) −117.3% · Bottom 25%
Operating margin (12 months) −83.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 4.7% · Above median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.59× · Cheaper than median
P/S (12 months) 3.07× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)24 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)98 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 2126
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 2126
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs 2126
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 2126
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 2126
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs 2126
argenx SE ARGX $927.21 $908.40 −2% vs 2126
CSL Limited CSL A$202.04 A$183.04 −9% vs 2126
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 2126
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 2126

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jw Cayman Therapeutics Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jw Cayman Therapeutics Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2126

Frequently asked questions

Is Jw Cayman Therapeutics Co Ltd (2126) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of HK$0.3900 versus a price of HK$2.50, about 84% lower (overvalued).
What is the fair value of 2126?
Our model-based fair value for Jw Cayman Therapeutics Co Ltd is HK$0.3900 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$2.50.
What is the quality score of 2126?
Jw Cayman Therapeutics Co Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jw Cayman Therapeutics Co Ltd (2126)?
Our model-based price target is the fair value of HK$0.3900 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario HK$0.2600, optimistic scenario HK$0.4900. It is a calculation from audited fundamentals, not an analyst target.
What is the Jw Cayman Therapeutics Co Ltd stock forecast for 2026?
Our models put fair value at HK$0.3900, about 84% lower versus a price of HK$2.50 (overvalued). Cautious scenario HK$0.2600, optimistic scenario HK$0.4900. The calculation is refreshed regularly with new filings.
What is the revenue of Jw Cayman Therapeutics Co Ltd (2126)?
Jw Cayman Therapeutics Co Ltd reported trailing-twelve-month revenue of about 289M CNY (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Jw Cayman Therapeutics Co Ltd (2126)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jw Cayman Therapeutics Co Ltd it is HK$0.3900 per share (as of Nov 8, 2026), against a price of HK$2.50. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Jw Cayman Therapeutics Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 2126 trades above its calculated fair value: price HK$2.50, fair value HK$0.3900, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2126?
No. The price is what the market pays today (HK$2.50); the fair value is what the company's own numbers justify (HK$0.3900). For Jw Cayman Therapeutics Co Ltd the two are HK$2.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jw Cayman Therapeutics Co Ltd worth?
The market values Jw Cayman Therapeutics Co Ltd at about HK$1.0B (market capitalisation, as of Nov 8, 2026). Per share that is HK$2.50; our models calculate a fair value of HK$0.3900 per share.
What do the bullish and bearish scenarios say about 2126?
Our models span a range for Jw Cayman Therapeutics Co Ltd: cautious scenario HK$0.2600, base HK$0.3900, optimistic HK$0.4900 per share (as of Nov 8, 2026, price HK$2.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jw Cayman Therapeutics Co Ltd (2126)?
Balance-sheet figures for Jw Cayman Therapeutics Co Ltd (as of Nov 8, 2026): return on equity −49.7%, debt of 0.03 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 2126 from its 52-week high?
Jw Cayman Therapeutics Co Ltd trades at HK$2.50, about 32% below its 52-week high of HK$3.70 and 67% above the low of HK$1.50 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.3900 is for.
Which stocks are comparable to Jw Cayman Therapeutics Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jw Cayman Therapeutics Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price HK$2.50, calculated fair value HK$0.3900 (−84%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2126 calculated?
We run Jw Cayman Therapeutics Co Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of HK$0.3900 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Jw Cayman Therapeutics Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jw Cayman Therapeutics Co Ltd (2126)?
The closing price on Nov 6, 2026 was HK$2.50. Our model-based fair value is HK$0.3900, about 84% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jw Cayman Therapeutics Co Ltd right now?
The price sits above even our optimistic bull case (HK$0.4900). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.2600 to HK$0.4900) leaves room in how you read the outcome.

Key figures of Jw Cayman Therapeutics Co Ltd

How large is the market capitalisation of Jw Cayman Therapeutics Co Ltd (2126)?
The market capitalisation of Jw Cayman Therapeutics Co Ltd is HK$1.0B (≈ $133M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jw Cayman Therapeutics Co Ltd (2126)?
The price-to-sales ratio of Jw Cayman Therapeutics Co Ltd is 3.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Jw Cayman Therapeutics Co Ltd (2126)?
The return on equity (ROE) of Jw Cayman Therapeutics Co Ltd is −49.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jw Cayman Therapeutics Co Ltd (2126)?
On an EBIT basis the return on assets of Jw Cayman Therapeutics Co Ltd is −28.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jw Cayman Therapeutics Co Ltd (2126)?
The operating margin of Jw Cayman Therapeutics Co Ltd is −83.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jw Cayman Therapeutics Co Ltd (2126)?
Revenue at Jw Cayman Therapeutics Co Ltd is growing +4.7% versus a year earlier (3y avg +23.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Jw Cayman Therapeutics Co Ltd (2126) generate?
The free cash flow of Jw Cayman Therapeutics Co Ltd is −78.5M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Jw Cayman Therapeutics Co Ltd (2126) hold?
Jw Cayman Therapeutics Co Ltd holds more cash than debt, 241M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Jw Cayman Therapeutics Co Ltd in the live analysis

One click puts Jw Cayman Therapeutics Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.